Iwabradyna Synthon

Ivabradine, the active ingredient in Iwabradyna Synthon, is an If channel inhibitor presented as an oral tablet for oral use. By selectively inhibiting the funny (If) current in the sinoatrial node, it lowers heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Iwabradyna Synthon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance through rigorous testing.

Ivabradine acts on cardiac pacemaker activity and is used in conditions where heart rate reduction improves outcomes.

- Chronic stable angina: reduces the frequency of angina attacks and improves exercise tolerance. - Heart failure with reduced ejection fraction: lowers heart rate, decreasing myocardial oxygen demand and reducing hospitalization risk. - Ischemic heart disease: helps control heart rate, alleviating symptoms related to myocardial ischemia.

Ivabradine may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Bradycardia: abnormally low heart rate. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache. - Dizziness. - Fatigue. - Nausea.

Serious or Rare Side Effects: - Severe bradycardia requiring medical intervention. - Symptomatic hypotension. - Atrial fibrillation. - Visual loss or persistent visual disturbances. - Cardiac arrest. - Severe allergic reactions (anaphylaxis).

When prescribing Ivabradine, several safety considerations should be observed.

- Heart rate monitoring: check resting heart rate before initiation and periodically thereafter. - Contraindication in severe hepatic impairment: avoid use or adjust dose. - Caution in patients with sick sinus syndrome or atrioventricular block: assess conduction status. - Use with caution when combined with other bradycardic agents such as beta‑blockers or digoxin. - Dose adjustment in renal impairment: evaluate renal function and modify dose if needed. - Store at room temperature: keep in the original package, protect from moisture and light.

Ivabradine can interact with other medicines, influencing its plasma levels or additive cardiac effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ivabradine exposure. - Other bradycardic agents (beta‑blockers, digoxin, diltiazem, verapamil): risk of excessive heart‑rate reduction. - Drugs that prolong AV conduction (e.g., amiodarone): can precipitate severe bradyarrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce ivabradine effectiveness. - Antihypertensive agents (e.g., ACE inhibitors, diuretics): monitor blood pressure and heart rate. - Concomitant use with QT‑prolonging drugs: observe for arrhythmias.